IFNG and neoplasm: Reducing the amount of circulating exosomal PD-L1, decreasing genetic PD-L1 expression in tumor cells, attenuating IFN-γ-induced PD-L1 adaptive immune tolerance and achieving downregulation of PD-L1 expression in tumor cells and exosomes.